Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Limited is an early-stage bioscience firm that researches, develops, and commercializes traditional Chinese medicine (TCM) formulas. The company focuses on formulas designed to treat neurocognitive disorders and degeneration, particularly attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). It operates primarily through its subsidiary, Regencell Bioscience Limited, in partnership with an experienced practitioner to develop standardized liquid-based formulations. The target patient population and end customers consist of individuals diagnosed with ADHD and ASD, along with their families and caregivers seeking alternative or holistic treatment options.

The company maintains its principal executive offices in Causeway Bay, Hong Kong, and holds corporate registration in the Cayman Islands. Its operations and clinical research activities are based primarily in Hong Kong, where it conducts efficacy trials with enrolled pediatric patients and collaborates with local practitioners. In addition to its active research entity, the organization maintains wholly owned corporate subsidiaries incorporated in Hong Kong and the British Virgin Islands for future operational needs.

Summary of the business section of Regencell Bioscience's latest annual report, written by StockData.